← All Novabay Pharmaceuticals, INC filings

Novabay Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NBY
Novabay Pharmaceuticals, INC
10-K/A: Stablecoin Development Corp. Restates 2025 Financials Due to Warrant Accounting Error
Stablecoin Development Corporation (formerly NovaBay Pharmaceuticals, Inc.) is restating its 2025 financial statements due to an accounting error related to common stock warrants, impacting warrant liability by $608.6 million.
NBY
Novabay Pharmaceuticals, INC
10-K: NovaBay Pivots to Digital Assets, Reports 2025 Financials
NovaBay Pharmaceuticals, Inc. has completed a significant business realignment, divesting its legacy pharmaceutical operations to focus on a blockchain-based digital asset strategy, primarily acquiring SKY tokens.
NBY
Novabay Pharmaceuticals, INC
10-K: NovaBay Pharmaceuticals Faces Uncertain Future After Asset Sales, Considers Dissolution
NovaBay Pharmaceuticals is evaluating strategic options, including a potential dissolution, after selling its Avenova and wound care assets.
NBY
Novabay Pharmaceuticals, INC
10-K/A: NovaBay Pharmaceuticals Files Amended 10-K to Include Missing Exhibit
NovaBay Pharmaceuticals has filed an amendment to its annual report on Form 10-K to include a previously omitted exhibit, with no other changes made to the original filing.
NBY
Novabay Pharmaceuticals, INC
10-K: NovaBay Pharmaceuticals Implements Non-Employee Director Compensation Plan and Files 10-K
NovaBay Pharmaceuticals outlines its non-employee director compensation plan and provides a comprehensive financial overview in its annual 10-K filing.